Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies
- 29 June 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (9) , 1810-1818
Abstract
Aim: To examine the efficacy of glucose‐lowering medications in subgroups of patients with type 2 diabetes mellitus (T2DM). Research design and methods: Cluster analysis was performed in participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study and the Qatar study using age, body mass index (BMI), glycated haemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA‐IR) and beta‐cell function (HOMA‐β). Participants also underwent an oral glucose tolerance test with measurement of plasma glucose, insulin and C‐peptide concentrations to derive independent measures of insulin secretion and insulin sensitivity. The response to glucose‐lowering therapies (change in HbA1c) was measured in each participant cluster for 3 years. Results: Three distinct and comparable clusters/groups of T2DM patients were identified in both the EDICT and Qatar studies. Participants in Group 1 had the highest HbA1c and manifested severe insulin deficiency. Participants in Group 3 had comparable insulin sensitivity to those in Group 1 but better beta‐cell function and better glucose control. Participants in Group 2 had the highest BMI with severe insulin resistance accompanied by marked hyperinsulinaemia, which was primarily attributable to decreased insulin clearance. Unexpectedly, participants in Group 1 had better response to combination therapy with pioglitazone plus exenatide than with insulin therapy or metformin sequentially followed by glipizide and basal insulin, while participants in Group 2 responded equally well to both therapies despite very severe insulin resistance. Conclusion: Distinct metabolic phenotypes characterize different T2DM clusters and differential responses to glucose‐lowering therapies. Participants with severe insulin deficiency respond better to agents that preserve beta‐cell function, while, surprisingly, patients with severe insulin resistance did not respond favourably to insulin sensitizers.Keywords
Funding Information
- National Institutes of Health
This publication has 23 references indexed in Scilit:
- In Vivo Actions of Peroxisome Proliferator–Activated ReceptorsDiabetes Care, 2013
- Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose ToleranceDiabetes, 2012
- Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Pathogenesis of Insulin Resistance in Skeletal MuscleJournal of Biomedicine and Biotechnology, 2010
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Thiazolidinediones improve β-cell function in type 2 diabetic patientsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose ToleranceDiabetes, 2006
- Effect of Pioglitazone on Pancreatic β-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational DiabetesDiabetes, 2006
- Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.Diabetes Care, 1999
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985